- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:30 | Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME | 160 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in... ► Artikel lesen | |
| 12:18 | Chugai Pharmaceutical Teams With Biomy For Development Of AI-based Cancer Pathology Program | 170 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies... ► Artikel lesen | |
| 06.11. | Rani Therapeutics announces $1.085 billion Chugai collaboration | 6 | Investing.com | ||
| 27.10. | Chugai acquires Renalys, enhancing its kidney disease portfolio | 2 | Pharmaceutical Technology | ||
| CHUGAI PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 24.10. | Chugai buys a kidney biotech; ICER targets rising launch prices | 4 | BioPharma Dive | ||
| 24.10. | Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries | 29 | FiercePharma | ||
| 24.10. | Chugai buys 'Asia lag' firm Renalys for $98m upfront | 3 | pharmaphorum | ||
| 24.10. | Chugai Pharmaceutical 9-month Net Income Rises | 304 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen,... ► Artikel lesen | |
| 23.10. | Roche axes 4 Chugai solid tumor assets in early-phase clearout | 10 | FierceBiotech | ||
| 17.10. | Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact | 12 | FierceBiotech | ||
| 17.10. | Rani Therapeutics surges on Chugai licensing deal, private placement | 31 | Seeking Alpha | ||
| 17.10. | Rani Therapeutics: Aktie schießt nach potenziellem Milliarden-Deal mit Chugai in die Höhe | 37 | Investing.com Deutsch | ||
| 17.10. | Rani Therapeutics stock soars after inking $1 billion potential deal with Chugai | 11 | Investing.com | ||
| 17.10. | Rani Therapeutics signs $1 billion potential deal with Chugai for oral biologics | 4 | Investing.com | ||
| 17.10. | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | 460 | GlobeNewswire (Europe) | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| 27.08. | Chugai spikes after Eli Lilly trial win for obesity pill | 23 | Seeking Alpha | ||
| 08.08. | Chugai stock drops the most since 1977 on disappointing obesity drug data | 32 | Japan Times | ||
| 24.07. | Chugai Pharmaceutical reports Q2 results | 9 | Seeking Alpha | ||
| 08.07. | Chugai and Gero link on antibody drugs for age-related conditions | 5 | Pharmaceutical Technology | ||
| 19.06. | NEC Corporation: NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment | 742 | JCN Newswire | - Identified the potential to reduce the time required to research and predict drug combinations by approximately 50% -TOKYO, June 18, 2025 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701), in collaboration... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 4,478 | -4,84 % | Trulieve Cannabis Corp.: Trulieve Reports Third Quarter 2025 Results Demonstrating Operational Discipline and Cash Flow Strength | Third quarter revenue of $288 million, with 59% gross margin
Year to date cash flow from operations of $214 million and free cash flow of $173 million*
Sold... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 235,10 | -1,14 % | West Pharmaceutical gibt auf Stephens-Konferenz optimistischen Ausblick | ||
| KALA BIO | 0,562 | +3,79 % | KALA BIO, Inc. - 10-Q, Quarterly Report | ||
| SHIONOGI | 14,800 | -1,33 % | Shionogi Announces Corporate Reorganization Following Japan Tobacco Pharma Merger | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. Thursday announced it will implement a corporate reorganization and several personnel reassignments, effective December 1, 2025, in line with the upcoming... ► Artikel lesen | |
| CHARLOTTES WEB | 0,058 | -9,45 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports Q3 2025 Results | Healthcare Focus, Product Innovation, and Cost Improvements
LOUISVILLE, Colo., Nov. 12, 2025 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF), Charlotte's Web Holdings,... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,450 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 03.07.2025 | The following instruments on XETRA do have their last trading day on 03.07.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 03.07.2025ISIN NameAU3CB0222354 FMO-N.FIN.-M.O. 2025... ► Artikel lesen | |
| LUYE PHARMA | 0,332 | 0,00 % | LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR THE GROUP'S NEW DRUG LY03017 FOR CLINICAL TRIALS IN THE U.S. | ||
| MIRUM PHARMACEUTICALS | 61,50 | -1,60 % | Mirum Pharmaceuticals, Inc. - 8-K, Current Report | ||
| PERCHERON THERAPEUTICS | 0,005 | +12,50 % | Edison Group: Edison Issues Report on Percheron Therapeutics (PER) | London, United Kingdom--(Newsfile Corp. - October 7, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)Percheron Therapeutics has reported final results from the Phase I dose escalation... ► Artikel lesen | |
| AYURCANN | 0,012 | 0,00 % | Ayurcann Holdings Corp: Ayurcann's fiscal 2025 revenue at $55.44-million | ||
| AVANT BRANDS | 0,448 | +4,19 % | Avant Brands Inc.: Avant Brands Announces Results for Q3 2025 | KELOWNA, BC / ACCESS Newswire / October 15, 2025 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BUP) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products... ► Artikel lesen | |
| KALBE FARMA | 0,060 | 0,00 % | Kalbe Farma profit rises 10.63%, shares react positively: The shares of this Indeks52 constituent climb 3.25% ... | ||
| EVEREST MEDICINES | 4,900 | +1,66 % | Everest Medicines Limited: Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders | HONG KONG, Oct 30, 2025 - (ACN Newswire) - Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. ('Visara'), a subsidiary of NovaBridge Biosciences... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 28,000 | -2,10 % | Kobayashi Pharmaceutical Q3 Net Profit Slips, But Sales Rise; Backs Annual Outlook | TOKYO (dpa-AFX) - Kobayashi Pharmaceutical Co. Ltd.(KBYPF, 4967.T) registered a decline in net profit for the third quarter. However, the company recorded an increase in sales, driven by the... ► Artikel lesen | |
| SILO WELLNESS | 0,008 | -100,00 % | Silo Wellness Inc.: Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of Business | Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - September 28, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo" or the "Company"), to be renamed Born Defense Inc., is pleased to announce that it... ► Artikel lesen |
CHUGAI PHARMACEUTICAL CO LTD ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,800 (-3,45 %) liegt der Kurs bei 22,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHUGAI PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.